• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

MUC1 通过 EGFR/PI3K/Akt 信号通路诱导肿瘤微环境中 Foxp3+Treg 细胞的积累,从而促进胆管癌的生长和转移。

MUC1 induces the accumulation of Foxp3 Treg cells in the tumor microenvironment to promote the growth and metastasis of cholangiocarcinoma through the EGFR/PI3K/Akt signaling pathway.

机构信息

Department of Hepatobiliary and Pancreatic Surgery, The Second Hospital of Jilin University, Changchun 130041, Jilin Province, PR China.

Department of Medicine, The Hospital of Northeast Normal University, Changchun 130024, Jilin Province, PR China.

出版信息

Int Immunopharmacol. 2023 May;118:110091. doi: 10.1016/j.intimp.2023.110091. Epub 2023 Apr 3.

DOI:10.1016/j.intimp.2023.110091
PMID:37018979
Abstract

Tumor microenvironment (TME) plays an important role in the progression of cholangiocarcinoma. This study aims to explore whether Mucin 1 (MUC1) regulates Foxp3 Treg cells in the TME of cholangiocarcinoma through the epidermal growth factor receptor (EGFR)/phosphatidylinositol-3-kinase (PI3K)/Akt signaling pathway. High-throughput sequencing dataset in the GEO database combined with GeneCards and Phenolyzer databases was used to obtain key genes in cholangiocarcinoma, followed by downstream pathway prediction. The relationship among MUC1, EGFR, and PI3K/Akt signaling pathway was explored. CD4 T cells extracted from peripheral blood were induced to differentiate into Treg cells, followed by co-culture with cholangiocarcinoma cells. A mouse model was constructed to detect the role of MUC1 in the accumulation of Foxp3 Treg cells, malignant phenotypes of cholangiocarcinoma, and tumorigenesis in vivo. MUC1, highly expressed in cholangiocarcinoma, might be involved in cholangiocarcinoma development. MUC1 interacted with the EGFR to activate the EGFR/PI3K/Akt signaling pathway. MUC1 overexpression could activate the EGFR/PI3K/Akt signaling pathway, which promoted the accumulation of Foxp3 Treg cells in the TME and the malignant phenotypes of cholangiocarcinoma cells both in vitro and in vivo and enhanced tumorigenesis in vivo. MUC1 may interact with EGFR to activate the EGFR/PI3K/Akt signaling pathway, which induces the accumulation of Foxp3 Treg cells, enhancing the malignant phenotypes of cholangiocarcinoma cells and tumorigenesis in vivo and ultimately augmenting cholangiocarcinoma growth and metastasis.

摘要

肿瘤微环境(TME)在胆管癌的进展中起着重要作用。本研究旨在探讨黏蛋白 1(MUC1)是否通过表皮生长因子受体(EGFR)/磷酸肌醇-3-激酶(PI3K)/Akt 信号通路调节胆管癌细胞中的 Foxp3 Treg 细胞。利用 GEO 数据库中的高通量测序数据集,结合 GeneCards 和 Phenolyzer 数据库,获得胆管癌中的关键基因,然后进行下游通路预测。探讨了 MUC1、EGFR 和 PI3K/Akt 信号通路之间的关系。从外周血中提取 CD4 T 细胞,诱导其分化为 Treg 细胞,然后与胆管癌细胞共培养。构建小鼠模型,检测 MUC1 在 Foxp3 Treg 细胞积累、胆管癌细胞恶性表型和体内肿瘤发生中的作用。MUC1 在胆管癌中高表达,可能参与胆管癌的发生发展。MUC1 与 EGFR 相互作用激活 EGFR/PI3K/Akt 信号通路。MUC1 过表达可激活 EGFR/PI3K/Akt 信号通路,促进 TME 中 Foxp3 Treg 细胞的积累以及胆管癌细胞的恶性表型,在体内增强肿瘤发生。MUC1 可能与 EGFR 相互作用激活 EGFR/PI3K/Akt 信号通路,诱导 Foxp3 Treg 细胞的积累,增强胆管癌细胞的恶性表型和体内肿瘤发生,从而最终促进胆管癌的生长和转移。

相似文献

1
MUC1 induces the accumulation of Foxp3 Treg cells in the tumor microenvironment to promote the growth and metastasis of cholangiocarcinoma through the EGFR/PI3K/Akt signaling pathway.MUC1 通过 EGFR/PI3K/Akt 信号通路诱导肿瘤微环境中 Foxp3+Treg 细胞的积累,从而促进胆管癌的生长和转移。
Int Immunopharmacol. 2023 May;118:110091. doi: 10.1016/j.intimp.2023.110091. Epub 2023 Apr 3.
2
MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways.MUC13通过表皮生长因子受体/磷脂酰肌醇-3激酶/蛋白激酶B通路促进肝内胆管癌进展。
J Hepatol. 2020 Apr;72(4):761-773. doi: 10.1016/j.jhep.2019.11.021. Epub 2019 Dec 16.
3
Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.三结构域蛋白 59(TRIM59)的敲低通过 PI3K/AKT/mTOR 信号通路抑制胆管癌细胞的增殖。
Gene. 2019 May 25;698:50-60. doi: 10.1016/j.gene.2019.02.044. Epub 2019 Feb 27.
4
Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.PI3K/AKT信号通路的激活增加与胆管癌转移相关,PI3K/mTOR抑制是一种可能的治疗策略。
Tumour Biol. 2013 Dec;34(6):3637-48. doi: 10.1007/s13277-013-0945-2. Epub 2013 Jul 6.
5
Atractylodin inhibited the migration and induced autophagy in cholangiocarcinoma cells via PI3K/AKT/mTOR and p38MAPK signalling pathways.苍术素通过 PI3K/AKT/mTOR 和 p38MAPK 信号通路抑制胆管癌细胞的迁移并诱导自噬。
J Pharm Pharmacol. 2021 Aug 12;73(9):1191-1200. doi: 10.1093/jpp/rgab036.
6
Mitochondrial transplantation inhibits cholangiocarcinoma cells growth by balancing oxidative stress tolerance through PTEN/PI3K/AKT signaling pathway.线粒体移植通过 PTEN/PI3K/AKT 信号通路平衡氧化应激耐受性抑制胆管癌细胞生长。
Tissue Cell. 2023 Dec;85:102243. doi: 10.1016/j.tice.2023.102243. Epub 2023 Oct 14.
7
Activation of the PI3K-AKT signaling pathway by SPARC contributes to the malignant phenotype of cholangiocarcinoma cells.基质细胞来源因子 1 通过激活 PI3K-AKT 信号通路促进胆管癌细胞的恶性表型。
Tissue Cell. 2022 Jun;76:101756. doi: 10.1016/j.tice.2022.101756. Epub 2022 Feb 10.
8
IL-8 is a novel prometastatic chemokine in intrahepatic cholangiocarcinoma that induces CXCR2-PI3K/AKT signaling upon CD97 activation.白细胞介素 8 是肝内胆管癌中一种新型的促转移趋化因子,它在 CD97 激活后诱导 CXCR2-PI3K/AKT 信号通路。
Sci Rep. 2023 Oct 31;13(1):18711. doi: 10.1038/s41598-023-45496-3.
9
ARHGAP21 Is Involved in the Carcinogenic Mechanism of Cholangiocarcinoma: A Study Based on Bioinformatic Analyses and Experimental Validation.ARHGAP21 参与胆管癌的致癌机制:基于生物信息学分析和实验验证的研究。
Medicina (Kaunas). 2023 Jan 10;59(1):139. doi: 10.3390/medicina59010139.
10
Akt expression may predict favorable prognosis in cholangiocarcinoma.Akt表达可能预示胆管癌的预后良好。
J Gastroenterol Hepatol. 2006 Nov;21(11):1744-51. doi: 10.1111/j.1440-1746.2006.04373.x.

引用本文的文献

1
Immunotherapy in biliary tract cancer: reshaping the tumour microenvironment and advancing precision combination strategies.胆管癌的免疫治疗:重塑肿瘤微环境与推进精准联合策略
Front Immunol. 2025 Aug 8;16:1651769. doi: 10.3389/fimmu.2025.1651769. eCollection 2025.
2
High cyclic GMP-AMP synthase and stimulator of interferon genes in cholangiocarcinoma suggest their potential as targets for treatment.胆管癌中高表达的环状GMP-AMP合酶和干扰素基因刺激因子提示它们有望成为治疗靶点。
PeerJ. 2025 Aug 6;13:e19800. doi: 10.7717/peerj.19800. eCollection 2025.
3
Mucin-1: a promising pan-cancer therapeutic target.
粘蛋白-1:一个有前景的泛癌治疗靶点。
NPJ Precis Oncol. 2025 Jul 2;9(1):218. doi: 10.1038/s41698-025-01016-2.
4
EGFR TKIs suppress MUC1 glycosylation through the PI3K/AKT/SP1/C1GALT1 pathway to enhance TnMUC1 CAR-T efficacy in EGFR-mutant NSCLC.表皮生长因子受体酪氨酸激酶抑制剂(EGFR TKIs)通过PI3K/AKT/SP1/C1GALT1途径抑制MUC1糖基化,以增强EGFR突变型非小细胞肺癌(NSCLC)中TnMUC1嵌合抗原受体T细胞(CAR-T)的疗效。
Cell Rep Med. 2025 Jul 15;6(7):102199. doi: 10.1016/j.xcrm.2025.102199. Epub 2025 Jun 24.
5
ID3 enhances PD-L1 expression by restructuring MYC to promote colorectal cancer immune evasion.ID3通过重塑MYC增强程序性死亡配体1(PD-L1)的表达,以促进结直肠癌免疫逃逸。
Proc Natl Acad Sci U S A. 2025 Apr 15;122(15):e2423490122. doi: 10.1073/pnas.2423490122. Epub 2025 Apr 10.
6
Pancreatic Cancer: Pathogenesis and Clinical Studies.胰腺癌:发病机制与临床研究
MedComm (2020). 2025 Apr 2;6(4):e70162. doi: 10.1002/mco2.70162. eCollection 2025 Apr.
7
Research progress of T cells in cholangiocarcinoma.胆管癌中T细胞的研究进展
Front Immunol. 2025 Feb 25;16:1453344. doi: 10.3389/fimmu.2025.1453344. eCollection 2025.
8
The Immune-Genomics of Cholangiocarcinoma: A Biological Footprint to Develop Novel Immunotherapies.胆管癌的免疫基因组学:开发新型免疫疗法的生物学印记。
Cancers (Basel). 2025 Jan 15;17(2):272. doi: 10.3390/cancers17020272.
9
: Precise Proteomics Technology for Mapping Receptor Protein Neighborhoods at the Cancer Cell Surface.用于绘制癌细胞表面受体蛋白邻域的精确蛋白质组学技术
Cancers (Basel). 2025 Jan 8;17(2):179. doi: 10.3390/cancers17020179.
10
Infiltrating T lymphocytes and tumor microenvironment within cholangiocarcinoma: immune heterogeneity, intercellular communication, immune checkpoints.胆管癌中的浸润性T淋巴细胞与肿瘤微环境:免疫异质性、细胞间通讯、免疫检查点
Front Immunol. 2025 Jan 8;15:1482291. doi: 10.3389/fimmu.2024.1482291. eCollection 2024.